Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

CMS Finalizes Controversial Biosimilars Payment Rule

This article was originally published in Scrip

Executive Summary

Ignoring the objections by several lawmakers and various lobbying groups, the Centers for Medicare & Medicaid Services (CMS) late last week finalized a rule it proposed in July that would lump biosimilars referenced on the same innovator into the same Medicare Part B reimbursement rate.



Related Companies